FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1967761175> ?p ?o ?g. }

• W1967761175 endingPage "212" @default.
• W1967761175 startingPage "205" @default.
• W1967761175 abstract "Androgens exert growth inhibitory effects on estrogen receptor and progesterone receptor-negative breast cancer cell lines that show androgen receptor expression. These laboratory findings may be translated into inexpensive alternative therapies for hormone receptor-negative invasive breast cancers. Our aim was to systematically evaluate androgen receptor expression by immunohistochemistry in invasive breast cancers. Androgen receptor (clone AR441, Dako) expression was analyzed on 189 well-characterized consecutive invasive breast carcinomas represented with threefold redundancy on tissue microarrays. Androgen receptor expression was semi-quantitated using a histochemical score-like method and a score >10 was considered positive. Of the 189 consecutive invasive breast cancers, 151 (80%) were positive and 38 (20%) were negative for androgen receptor. The majority (95%) of estrogen receptor-positive tumors were also androgen receptor positive. Of the estrogen receptor-negative tumors, androgen receptor reactivity was seen in 3 of 30 (10%) triple-negative cases and in 5/8 (63%) estrogen receptor-negative/progesterone receptor-negative/HER2+ cases. Six of eight estrogen receptor-negative/androgen receptor-positive cases showed apocrine differentiation. Androgen receptor expression in estrogen receptor-positive cases was associated with smaller tumor size (P=0.0001), lower Nottingham grade (P=0.002) and less frequent tumor cell necrosis (P=0.0001). Androgen receptor expression in estrogen receptor-negative tumors was associated with lower Nottingham grade (P=0.005) and apocrine differentiation (P=0.039). In conclusion, most estrogen receptor-positive breast tumors also express androgen receptor. Androgen receptor expression in estrogen receptor-negative/progesterone receptor-negative/HER2+ tumors (which commonly show apocrine differentiation) and a subset of triple - negative apocrine tumors suggest that these tumors together comprises the 'molecular apocrine' group described previously. However, these findings should be further confirmed on larger series of triple-negative and estrogen negative/progesterone negative/HER2+ tumors. Androgen receptor-targeted therapy in estrogen/progesterone receptor-negative tumors may provide an inexpensive alternative to usual high-dose chemotherapy with or without trastuzumab." @default.
• W1967761175 created "2016-06-24" @default.
• W1967761175 creator A5005474369 @default.
• W1967761175 creator A5023468026 @default.
• W1967761175 creator A5034149172 @default.
• W1967761175 creator A5054689523 @default.
• W1967761175 creator A5086373614 @default.
• W1967761175 date "2009-11-06" @default.
• W1967761175 modified "2023-10-18" @default.
• W1967761175 title "Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation" @default.
• W1967761175 cites W1511371042 @default.
• W1967761175 cites W1536290683 @default.
• W1967761175 cites W1598969217 @default.
• W1967761175 cites W1892496998 @default.
• W1967761175 cites W1993541773 @default.
• W1967761175 cites W2007385180 @default.
• W1967761175 cites W2009302893 @default.
• W1967761175 cites W2012140938 @default.
• W1967761175 cites W2015756684 @default.
• W1967761175 cites W2022939574 @default.
• W1967761175 cites W2029059005 @default.
• W1967761175 cites W2038451517 @default.
• W1967761175 cites W2039680999 @default.
• W1967761175 cites W2043152591 @default.
• W1967761175 cites W2044638220 @default.
• W1967761175 cites W2044769828 @default.
• W1967761175 cites W2046870043 @default.
• W1967761175 cites W2053741141 @default.
• W1967761175 cites W2056556973 @default.
• W1967761175 cites W2064469818 @default.
• W1967761175 cites W2065796923 @default.
• W1967761175 cites W2068773920 @default.
• W1967761175 cites W2074957208 @default.
• W1967761175 cites W2091120437 @default.
• W1967761175 cites W2097255042 @default.
• W1967761175 cites W2102596641 @default.
• W1967761175 cites W2123210834 @default.
• W1967761175 cites W2131994307 @default.
• W1967761175 cites W2132619562 @default.
• W1967761175 cites W2136460880 @default.
• W1967761175 cites W2136655134 @default.
• W1967761175 cites W2140834095 @default.
• W1967761175 cites W2146267790 @default.
• W1967761175 cites W2147343434 @default.
• W1967761175 cites W2149908785 @default.
• W1967761175 cites W2157285286 @default.
• W1967761175 cites W2157840751 @default.
• W1967761175 cites W2169260048 @default.
• W1967761175 cites W3126209173 @default.
• W1967761175 doi "https://doi.org/10.1038/modpathol.2009.159" @default.
• W1967761175 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19898421" @default.
• W1967761175 hasPublicationYear "2009" @default.
• W1967761175 type Work @default.
• W1967761175 sameAs 1967761175 @default.
• W1967761175 citedByCount "330" @default.
• W1967761175 countsByYear W19677611752012 @default.
• W1967761175 countsByYear W19677611752013 @default.
• W1967761175 countsByYear W19677611752014 @default.
• W1967761175 countsByYear W19677611752015 @default.
• W1967761175 countsByYear W19677611752016 @default.
• W1967761175 countsByYear W19677611752017 @default.
• W1967761175 countsByYear W19677611752018 @default.
• W1967761175 countsByYear W19677611752019 @default.
• W1967761175 countsByYear W19677611752020 @default.
• W1967761175 countsByYear W19677611752021 @default.
• W1967761175 countsByYear W19677611752022 @default.
• W1967761175 countsByYear W19677611752023 @default.
• W1967761175 crossrefType "journal-article" @default.
• W1967761175 hasAuthorship W1967761175A5005474369 @default.
• W1967761175 hasAuthorship W1967761175A5023468026 @default.
• W1967761175 hasAuthorship W1967761175A5034149172 @default.
• W1967761175 hasAuthorship W1967761175A5054689523 @default.
• W1967761175 hasAuthorship W1967761175A5086373614 @default.
• W1967761175 hasBestOaLocation W19677611751 @default.
• W1967761175 hasConcept C121608353 @default.
• W1967761175 hasConcept C126322002 @default.
• W1967761175 hasConcept C134018914 @default.
• W1967761175 hasConcept C170493617 @default.
• W1967761175 hasConcept C172313692 @default.
• W1967761175 hasConcept C2777164284 @default.
• W1967761175 hasConcept C2777911890 @default.
• W1967761175 hasConcept C2780192828 @default.
• W1967761175 hasConcept C2993002077 @default.
• W1967761175 hasConcept C502942594 @default.
• W1967761175 hasConcept C530470458 @default.
• W1967761175 hasConcept C61367390 @default.
• W1967761175 hasConcept C71315377 @default.
• W1967761175 hasConcept C71924100 @default.
• W1967761175 hasConcept C84606932 @default.
• W1967761175 hasConcept C86803240 @default.
• W1967761175 hasConcept C96307122 @default.
• W1967761175 hasConcept C98717036 @default.
• W1967761175 hasConceptScore W1967761175C121608353 @default.
• W1967761175 hasConceptScore W1967761175C126322002 @default.
• W1967761175 hasConceptScore W1967761175C134018914 @default.
• W1967761175 hasConceptScore W1967761175C170493617 @default.
• W1967761175 hasConceptScore W1967761175C172313692 @default.
• W1967761175 hasConceptScore W1967761175C2777164284 @default.

• next